In some studies, CAR-T therapies result in antigen escape/loss, and the rate of CD19-negative recurrence in ALL patients is 7%-25% (14–16, 34, 45, 46), while more patients have CD19-positive recurrence. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.